MA-BRIGHTCOVE
5.3.2024 15:04:33 CET | Business Wire | Press release
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today announced it is welcoming MotoAmerica, North America’s premier motorcycle road race series, to its roster of media customers. As the official streaming provider for MotoAmerica, Brightcove will power the live and video-on-demand (VOD) capabilities of the MotoAmerica Live+ streaming service, which will exclusively broadcast the upcoming 82nd running of the Daytona 200 (March 7-9, 2024).
“Delivering quality live and on-demand streaming experiences is essential for today’s sports and entertainment organizations to reach and engage their audiences effectively,” said Marc DeBevoise, CEO of Brightcove. “We’re happy to partner with MotoAmerica to help them deliver a unique viewing experience for fans worldwide. Through our award-winning platform, MotoAmerica will now be able to monetize its content on a global scale and drive additional revenue.”
“MotoAmerica began the journey into live-streaming motorcycle racing events in 2019. Throughout the years, we’ve received feedback from our fans to enhance the viewing experience,” said MotoAmerica COO Chuck Aksland. “In response, we decided to collaborate with Brightcove to offer our fans the upgraded experience they have been asking for. With the new platform provided by Brightcove, MotoAmerica can incorporate additional elements into the overall viewing experience. These elements include integrated live timing, betting options, news updates, merchandise offerings, and access to the 24-hour all-motorsports channel MTRSPT1, all in one location. Partnering with Brightcove ensures that both current and new fans of MotoAmerica can enjoy the best viewing experience possible. We are very excited about the improvements and are confident that our fans will appreciate the enhanced features and functionality now available to them.”
To tune in to MotoAmerica's action, fans can subscribe to MotoAmerica’s live streaming service, MotoAmerica Live+. Subscribers can watch races in all MotoAmerica classes live or on-demand and view highlights, interviews, and races from years past.
MotoAmerica joins a roster of professional sports organizations currently deploying Brightcove’s technology to connect with their fans, including Atlantic Coast Conference (ACC) Raycom Sports, ATP Tour, Badminton Horse Trials, Canadian Football League, Confederation of North, Central America and Caribbean Association Football (Concacaf), Harness Racing Victoria, Little League Baseball and Softball, Major League Soccer (MLS), National Hockey League (NHL), National Hot Rod Association (NHRA), U.S. Ski & Snowboard, United States Olympic and Paralympic Committee, United World Wrestling and USA Volleyball.
The addition of MotoAmerica further demonstrates Brightcove as the world’s leading streaming technology partner with a reliable, scalable, and flexible platform trusted by some of the most prominent sports entities in the world.
For more information, visit Brightcove.com.
About MotoAmerica
MotoAmerica is North America’s premier motorcycle road racing series. Established in 2014, MotoAmerica is home to the AMA Superbike Championship as well as additional classes, including Supersport, Stock 1000, Twins Cup, Junior Cup, and King Of The Baggers. MotoAmerica is an affiliate of KRAVE Group LLC, a partnership including three-time 500cc World Champion, two-time AMA Superbike Champion, and AMA Hall of Famer Wayne Rainey; ex-racer and former manager of Team Roberts Chuck Aksland; motorsports marketing executive Terry Karges; and businessman Richard Varner. For more information, please visit www.MotoAmerica.com and follow MotoAmerica on Facebook, Instagram, TikTok, Twitter, and YouTube.
About Brightcove Inc.
Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow Brightcove on LinkedIn, X (Formerly Twitter), Facebook, Instagram, Threads, and YouTube. Visit Brightcove.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305118283/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom